New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.
暂无分享,去创建一个
Oleksii S. Rukhlenko | Richard G Posner | William S Hlavacek | Oleksii S Rukhlenko | Boris N Kholodenko | B. Kholodenko | W. S. Hlavacek | R. Posner | Keesha E. Erickson | Keesha E Erickson | W. Hlavacek
[1] D. Bar-Sagi,et al. Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2 , 1996, Molecular and cellular biology.
[2] Jens Timmer,et al. Systems-level interactions between insulin–EGF networks amplify mitogenic signaling , 2009, Molecular systems biology.
[3] G. L. Hamilton,et al. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. , 2017, ACS chemical biology.
[4] B. Kholodenko,et al. Nonlinear signalling networks and cell-to-cell variability transform external signals into broadly distributed or bimodal responses , 2014, Journal of The Royal Society Interface.
[5] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[6] D T Denhardt,et al. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. , 1996, The Biochemical journal.
[7] J. Licht,et al. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. , 2006, Trends in cell biology.
[8] M. Mann,et al. Comparative Proteomic Analysis of Eleven Common Cell Lines Reveals Ubiquitous but Varying Expression of Most Proteins* , 2012, Molecular & Cellular Proteomics.
[9] J. Pessin,et al. Insulin and Epidermal Growth Factor Receptors Regulate Distinct Pools of Grb2-SOS in the Control of Ras Activation* , 1996, The Journal of Biological Chemistry.
[10] William S. Hlavacek,et al. Relaxation oscillations and hierarchy of feedbacks in MAPK signaling , 2017, Scientific Reports.
[11] R. Joseph,et al. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma , 2014, Drug design, development and therapy.
[12] Alfred Wittinghofer,et al. GEFs and GAPs: Critical Elements in the Control of Small G Proteins , 2007, Cell.
[13] Dave Trinel,et al. Optimization of ERK Activity Biosensors for both Ratiometric and Lifetime FRET Measurements , 2014, Sensors.
[14] James S. Duncan,et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. , 2015, Cell reports.
[15] J. Pessin,et al. SOS Phosphorylation and Disassociation of the Grb2-SOS Complex by the ERK and JNK Signaling Pathways (*) , 1996, The Journal of Biological Chemistry.
[16] A. Gingras,et al. The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1. , 2014, Cancer cell.
[17] E. Lander,et al. Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.
[18] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[19] M. Clausen,et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. , 2016, Drug discovery today.
[20] T. Meyer,et al. Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca2+/calmodulin , 2005, The Journal of cell biology.
[21] Boris N Kholodenko,et al. Scaffolding Protein Grb2-associated Binder 1 Sustains Epidermal Growth Factor-induced Mitogenic and Survival Signaling by Multiple Positive Feedback Loops* , 2006, Journal of Biological Chemistry.
[22] Nils Blüthgen,et al. Effects of sequestration on signal transduction cascades , 2006, The FEBS journal.
[23] B. Kholodenko,et al. The topology design principles that determine the spatiotemporal dynamics of G-protein cascades. , 2012, Molecular Biosystems.
[24] Eric Legius,et al. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation , 2008, Human mutation.
[25] Malte Schmick,et al. KRas Localizes to the Plasma Membrane by Spatial Cycles of Solubilization, Trapping and Vesicular Transport , 2014, Cell.
[26] C. Der,et al. The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. , 2011, Genes & cancer.
[27] Holger Sondermann,et al. Regulation of Ras Signaling Dynamics by Sos-Mediated Positive Feedback , 2006, Current Biology.
[28] John G. Albeck,et al. Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. , 2013, Molecular cell.
[29] Renaud Vincentelli,et al. Quantifying domain-ligand affinities and specificities by high-throughput holdup assay , 2015, Nature Methods.
[30] Yi Liu,et al. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.
[31] John C. Hunter,et al. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.
[32] Hans Clevers,et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening , 2016, eLife.
[33] Stefan Wetzel,et al. Small-molecule inhibition of APT1 affects Ras localization and signaling. , 2010, Nature chemical biology.
[34] Martin Kircher,et al. Deep proteome and transcriptome mapping of a human cancer cell line , 2011, Molecular systems biology.
[35] Walter Kolch,et al. Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients , 2015, Science Signaling.
[36] B. Kholodenko. Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects. , 2015, Cell reports.
[37] M. Lythgoe,et al. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. , 2013, Molecular cell.
[38] M. Selbach,et al. Global quantification of mammalian gene expression control , 2011, Nature.
[39] Ruedi Aebersold,et al. Mass-spectrometric exploration of proteome structure and function , 2016, Nature.
[40] Boris N. Kholodenko,et al. Bimodal Protein Distributions in Heterogeneous Oscillating Systems , 2012, CMSB.
[41] Eric S. Lander,et al. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras , 2017, Cell.
[42] D. Morrison,et al. Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.
[43] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[44] R. Gillies,et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer , 2016, Science Translational Medicine.
[45] Philipp Selenko,et al. Cell signaling, post-translational protein modifications and NMR spectroscopy , 2012, Journal of biomolecular NMR.
[46] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[47] Mohammad Reza Ahmadian,et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders , 2011, Human mutation.
[48] L. Kay,et al. NMR spectroscopy brings invisible protein states into focus. , 2009, Nature chemical biology.
[49] B. Kholodenko,et al. Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. , 2000, European journal of biochemistry.
[50] D. Bar-Sagi,et al. Ras effectors and their role in mitogenesis and oncogenesis , 1997, Journal of Molecular Medicine.
[51] Carla Mattos,et al. A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.
[52] S. Khozin,et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. , 2014, The oncologist.
[53] M. Clausen,et al. FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.
[54] J. Schlessinger,et al. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[55] Ozlem Keskin,et al. GTP-Dependent K-Ras Dimerization. , 2015, Structure.
[56] Ronald J. Moore,et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.
[57] T Aittokallio,et al. Cancer stem cell drugs target K-ras signaling in a stemness context , 2016, Oncogene.
[58] B. Kholodenko,et al. Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.
[59] Matthew S. Creamer,et al. Use of mechanistic models to integrate and analyze multiple proteomic datasets. , 2015, Biophysical journal.
[60] R. Wilson,et al. Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation , 2016, Oncotarget.
[61] A. Aplin,et al. Targeting mutant NRAS signaling pathways in melanoma. , 2016, Pharmacological research.
[62] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[63] Mohammad Reza Ahmadian,et al. Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes. , 2013, Human molecular genetics.
[64] D. Morrison,et al. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. , 2001, Molecular cell.
[65] S. Marqusee,et al. A Ras-induced conformational switch in the Ras activator Son of sevenless , 2006, Proceedings of the National Academy of Sciences.
[66] Steven P Gygi,et al. Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases , 2010, Science Signaling.
[67] Franziska Michor,et al. Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. , 2017, Cancer research.
[68] Noo Li Jeon,et al. Molecular Systems Biology Peer Review Process File Frequency Modulation of Erk Activation Dynamics Rewires Cell Fate Transaction Report , 2022 .
[69] Jayajit Das,et al. Digital Signaling and Hysteresis Characterize Ras Activation in Lymphoid Cells , 2009, Cell.
[70] Levi A Garraway,et al. Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.
[71] J. Colicelli,et al. Human RAS Superfamily Proteins and Related GTPases , 2004, Science's STKE.
[72] Mohammad Reza Ahmadian,et al. Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras , 1997, Nature Structural Biology.
[73] F. McCormick,et al. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. , 1987, Science.
[74] E. Gilles,et al. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.
[75] L. Kay,et al. Observing biological dynamics at atomic resolution using NMR. , 2009, Trends in biochemical sciences.
[76] A. Wittinghofer,et al. Kinetic analysis by fluorescence of the interaction between Ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25Mm. , 1998, Biochemistry.
[77] E. Stites,et al. A computational panel of pathological RAS mutants with implications for personalized medicine and genetic medicine , 2017, bioRxiv.
[78] Nicolas André,et al. Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. , 2016, Cancer research.
[79] P. Bastiaens,et al. Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling , 2013, Nature.
[80] D. Warburton,et al. mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins. , 2002, American journal of physiology. Lung cellular and molecular physiology.
[81] Boris N. Kholodenko,et al. Signalling ballet in space and time , 2010, Nature Reviews Molecular Cell Biology.
[82] Edward C Stites,et al. Network Analysis of Oncogenic Ras Activation in Cancer , 2007, Science.
[83] W. Hsu,et al. Phosphoproteomics Identifies Oncogenic Ras Signaling Targets and Their Involvement in Lung Adenocarcinomas , 2011, PloS one.
[84] G. Ladds,et al. Feedback activation of neurofibromin terminates growth factor-induced Ras activation , 2016, Cell Communication and Signaling.
[85] The developing story of Sprouty and cancer , 2014, Cancer and Metastasis Reviews.
[86] Holger Sondermann,et al. Structural Analysis of Autoinhibition in the Ras Activator Son of Sevenless , 2004, Cell.
[87] Boris N Kholodenko,et al. Long-range signaling by phosphoprotein waves arising from bistability in protein kinase cascades , 2006, Molecular systems biology.
[88] Kevan M. Shokat,et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.
[89] David R. Gilbert,et al. Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway , 2009, BMC Systems Biology.
[90] Alexandro E. Trevino,et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.
[91] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[92] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[93] B. Weber,et al. SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant , 2004, Cancer Research.
[94] Yiling Lu,et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.
[95] Mitsuhiko Ikura,et al. Integrated RAS signaling defined by parallel NMR detection of effectors and regulators. , 2014, Nature chemical biology.
[96] I. Verlaan,et al. Regulating c-Ras function cholesterol depletion affects caveolin association, GTP loading, and signaling , 2001, Current Biology.
[97] Oliver E. Sturm,et al. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. , 2005, The Biochemical journal.
[98] J. Cherfils,et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? , 2010, Nature Reviews Cancer.
[99] K. Guan,et al. Desensitization of Ras Activation by a Feedback Disassociation of the SOS-Grb2 Complex (*) , 1995, The Journal of Biological Chemistry.
[100] Edward C. Stites,et al. Differences in sensitivity to EGFR inhibitors could be explained by described biochemical differences between oncogenic Ras mutants , 2014, bioRxiv.
[101] Kwang-Hyun Cho,et al. Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway , 2009, Journal of Cell Science.
[102] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[103] J. Hancock,et al. Ras trafficking, localization and compartmentalized signalling. , 2012, Seminars in cell & developmental biology.
[104] J. Eccleston,et al. Fluorescence approaches to the study of the p21ras GTPase mechanism. , 1991, Biochemical Society transactions.
[105] D. Matallanas,et al. Distinct Utilization of Effectors and Biological Outcomes Resulting from Site-Specific Ras Activation: Ras Functions in Lipid Rafts and Golgi Complex Are Dispensable for Proliferation and Transformation , 2006, Molecular and Cellular Biology.
[106] Robert A Gatenby,et al. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies , 2017, bioRxiv.
[107] R. Pazdur,et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. , 2003, The oncologist.
[108] F. McCormick,et al. Biochemical Characterization of a Novel KRAS Insertion Mutation from a Human Leukemia* , 1996, The Journal of Biological Chemistry.
[109] Peter K. Sorger,et al. Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway , 2016, Science Signaling.
[110] A. Brunet,et al. Growth factor‐stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1) , 1994, FEBS letters.
[111] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[112] A. Aplin,et al. Mechanisms of resistance to RAF inhibitors in melanoma , 2011, The Journal of investigative dermatology.
[113] Boris N Kholodenko,et al. Spatially distributed cell signalling , 2009, FEBS letters.
[114] B. Kholodenko,et al. The dynamic control of signal transduction networks in cancer cells , 2015, Nature Reviews Cancer.
[115] M. Mann,et al. Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells , 2014, Nature Methods.
[116] B. Kholodenko,et al. Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades , 2004, The Journal of cell biology.
[117] Jungho Kim,et al. Kinetic mechanisms of mutation-dependent Harvey Ras activation and their relevance for the development of Costello syndrome. , 2013, Biochemistry.
[118] Ronald J. Hause,et al. Comprehensive Binary Interaction Mapping of SH2 Domains via Fluorescence Polarization Reveals Novel Functional Diversification of ErbB Receptors , 2012, PloS one.
[119] P. Bastiaens,et al. Identification of pyrazolopyridazinones as PDEδ inhibitors , 2016, Nature Communications.
[120] E. Castellano,et al. Functional specificity of ras isoforms: so similar but so different. , 2011, Genes & cancer.
[121] Gavin MacBeath,et al. Quantifying protein–protein interactions in high throughput using protein domain microarrays , 2010, Nature Protocols.
[122] Larry Rubinstein,et al. The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. , 2017, Cancer research.
[123] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[124] Thierry Mora,et al. Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves , 2016, bioRxiv.
[125] B N Kholodenko,et al. Signal processing at the Ras circuit: what shapes Ras activation patterns? , 2004, Systems biology.
[126] D. Esposito,et al. Dragging ras back in the ring. , 2014, Cancer cell.
[127] Mohammad Reza Ahmadian,et al. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions , 2016, PloS one.
[128] B. Druker,et al. Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib , 2003, Pharmacological Reviews.
[129] Christina Kiel,et al. Structure‐energy‐based predictions and network modelling of RASopathy and cancer missense mutations , 2014, Molecular systems biology.
[130] D. Fell,et al. Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells , 2000, FEBS letters.
[131] K. Gerwert,et al. Ras catalyzes GTP hydrolysis by shifting negative charges from gamma- to beta-phosphate as revealed by time-resolved FTIR difference spectroscopy. , 2001, Biochemistry.
[132] Anne-Claude Gingras,et al. Evolution of AF6-RAS association and its implications in mixed-lineage leukemia , 2017, Nature Communications.
[133] Bernd Bodenmiller,et al. Influence of node abundance on signaling network state and dynamics analyzed by mass cytometry , 2017, Nature Biotechnology.
[134] Andre Hoelz,et al. Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOS , 2003, Cell.
[135] Boris N. Kholodenko,et al. Emergence of bimodal cell population responses from the interplay between analog single-cell signaling and protein expression noise , 2012, BMC Systems Biology.
[136] R. Goody,et al. Kinetics of interaction of nucleotides with nucleotide-free H-ras p21. , 1990, Biochemistry.
[137] Gideon Bollag,et al. GTPase activating proteins: critical regulators of intracellular signaling. , 2002, Biochimica et biophysica acta.
[138] M. Mann,et al. The coming age of complete, accurate, and ubiquitous proteomes. , 2013, Molecular cell.
[139] P. Sorger,et al. Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.
[140] Jonathan D. Licht,et al. Mammalian Sprouty Proteins Inhibit Cell Growth and Differentiation by Preventing Ras Activation* , 2001, The Journal of Biological Chemistry.
[141] Ultan McDermott,et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.
[142] K. Svoboda,et al. A genetically encoded fluorescent sensor of ERK activity , 2008, Proceedings of the National Academy of Sciences.
[143] Jay T. Groves,et al. Ras activation by SOS: Allosteric regulation by altered fluctuation dynamics , 2014, Science.
[144] R. Beroukhim,et al. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. , 2013, Cancer cell.
[145] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[146] Jared E. Toettcher,et al. Using Optogenetics to Interrogate the Dynamic Control of Signal Transmission by the Ras/Erk Module , 2013, Cell.
[147] Alexander R A Anderson,et al. Phase i trials in melanoma: A framework to translate preclinical findings to the clinic. , 2016, European journal of cancer.
[148] Timothy A. Whitehead,et al. Determination of binding affinity upon mutation for type I dockerin–cohesin complexes from Clostridium thermocellum and Clostridium cellulolyticum using deep sequencing , 2016, Proteins.
[149] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[150] C. Mattos,et al. Allosteric modulation of Ras positions Q61 for a direct role in catalysis , 2010, Proceedings of the National Academy of Sciences.
[151] Ruedi Aebersold,et al. Quantification of ErbB network proteins in three cell types using complementary approaches identifies cell-general and cell-type-specific signaling proteins. , 2014, Journal of proteome research.
[152] O. Carugo,et al. A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal , 2009, Nature Structural &Molecular Biology.
[153] S. Dhanasekaran,et al. KRAS Engages AGO2 to Enhance Cellular Transformation. , 2016, Cell reports.
[154] B. Kholodenko,et al. Signalling over a distance: gradient patterns and phosphorylation waves within single cells. , 2010, Biochemical Society transactions.
[155] F. Gnad,et al. Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics* , 2013, Molecular & Cellular Proteomics.
[156] G. Keating. Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer , 2014, Drugs.
[157] K. Ravichandran,et al. Cooperation between Noncanonical Ras Network Mutations. , 2015, Cell reports.
[158] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[159] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[160] R. Goody,et al. Individual rate constants for the interaction of Ras proteins with GTPase-activating proteins determined by fluorescence spectroscopy. , 1997, Biochemistry.
[161] Ming Zhou,et al. Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.
[162] Marco Y. Hein,et al. A “Proteomic Ruler” for Protein Copy Number and Concentration Estimation without Spike-in Standards* , 2014, Molecular & Cellular Proteomics.
[163] G. Guy,et al. Sprouty Proteins Are Targeted to Membrane Ruffles upon Growth Factor Receptor Tyrosine Kinase Activation , 2000, The Journal of Biological Chemistry.
[164] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[165] Jacob J. Hughey,et al. High-Sensitivity Measurements of Multiple Kinase Activities in Live Single Cells , 2014, Cell.
[166] Y. Yarden,et al. Phosphorylation of Carboxyl-terminal Tyrosines Modulates the Specificity of Sprouty-2 Inhibition of Different Signaling Pathways* , 2005, Journal of Biological Chemistry.
[167] M. Ahmadian,et al. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation. , 2010, Human molecular genetics.
[168] John V Heymach,et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.
[169] Pablo Rodriguez-Viciana,et al. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. , 2006, Molecular cell.
[170] Christopher A. Voigt,et al. Spatiotemporal Control of Cell Signalling Using A Light-Switchable Protein Interaction , 2009, Nature.
[171] I. Huvar,et al. A decrease in the intracellular guanosine 5'-triphosphate concentration is necessary for granulocytic differentiation of HL-60 cells, but growth cessation and differentiation are not associated with a change in the activation state of Ras, the transforming principle of HL-60 cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[172] K. Ravichandran,et al. Mechanistic modeling to investigate signaling by oncogenic Ras mutants , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[173] Mitsuhiko Ikura,et al. NMR-based functional profiling of RASopathies and oncogenic RAS mutations , 2013, Proceedings of the National Academy of Sciences.
[174] Karel Svoboda,et al. The Spread of Ras Activity Triggered by Activation of a Single Dendritic Spine , 2008, Science.
[175] M. Barbacid. ras genes. , 1987, Annual review of biochemistry.
[176] David A. Williams,et al. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease , 2016, American journal of hematology/oncology.
[177] Kuen-Feng Chen,et al. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells , 2016, Oncotarget.
[178] A. Wittinghofer,et al. Monitoring the GAP catalyzed H-Ras GTPase reaction at atomic resolution in real time , 2001, Proceedings of the National Academy of Sciences of the United States of America.